AU2001252147A1 - Farnesyl protein transferase inhibitor combinations - Google Patents

Farnesyl protein transferase inhibitor combinations

Info

Publication number
AU2001252147A1
AU2001252147A1 AU2001252147A AU5214701A AU2001252147A1 AU 2001252147 A1 AU2001252147 A1 AU 2001252147A1 AU 2001252147 A AU2001252147 A AU 2001252147A AU 5214701 A AU5214701 A AU 5214701A AU 2001252147 A1 AU2001252147 A1 AU 2001252147A1
Authority
AU
Australia
Prior art keywords
protein transferase
transferase inhibitor
farnesyl protein
inhibitor combinations
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001252147A
Inventor
Mary Ellen Margaret Rybak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2001252147A1 publication Critical patent/AU2001252147A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AU2001252147A 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations Abandoned AU2001252147A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200693 2000-02-29
EP00200693 2000-02-29
PCT/EP2001/002169 WO2001064218A2 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations

Publications (1)

Publication Number Publication Date
AU2001252147A1 true AU2001252147A1 (en) 2001-09-12

Family

ID=8171112

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001252147A Abandoned AU2001252147A1 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations

Country Status (6)

Country Link
US (1) US20030125326A1 (en)
EP (1) EP1261342A2 (en)
JP (1) JP2003525245A (en)
AU (1) AU2001252147A1 (en)
CA (1) CA2397694A1 (en)
WO (1) WO2001064218A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1552020B1 (en) 2002-10-18 2012-02-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Lmna gene and its involvement in hutchinson-gilford progeria syndrome (hgps) and arteriosclerosis
US7838531B2 (en) * 2002-10-18 2010-11-23 The United States Of America As Represented By The Department Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
AU2004298486A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
CA2559221A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20070213366A1 (en) 2005-12-23 2007-09-13 Justman Craig J Treatment of Synucleinopathies
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
JP2012508768A (en) 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション Azaquinolinone derivatives and uses thereof
LT2909192T (en) 2012-10-16 2017-07-10 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
ES2628365T3 (en) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Phenyl-linked quinolinyl modulators of ROR-GAMA-T
CA2888480C (en) 2012-10-16 2021-03-16 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of ror.gamma.t
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
KR20160070133A (en) 2013-10-15 2016-06-17 얀센 파마슈티카 엔.브이. Alkyl Linked Quinolinyl modulators of RORyt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
EP3057422B1 (en) 2013-10-15 2019-05-15 Janssen Pharmaceutica NV Quinolinyl modulators of ror(gamma)t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0836383A1 (en) * 1995-06-29 1998-04-22 Merck & Co., Inc. Combinations of inhibitors of farnesyl-protein transferase
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
CA2231105C (en) * 1995-12-08 2005-09-13 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
US6013662A (en) * 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
ATE366250T1 (en) * 1997-04-25 2007-07-15 Janssen Pharmaceutica Nv QUINAZOLINONES INHIBIT FARNESYL TRANSFERASE
FR2772764B1 (en) * 1997-12-23 2000-01-14 Rhone Poulenc Rorer Sa NOVEL FARNESYLE TRANSFERASE INHIBITORS, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND THEIR USE IN THE PREPARATION OF MEDICAMENTS
AU4562799A (en) * 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6358985B1 (en) * 1998-07-02 2002-03-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP4725940B2 (en) * 1998-12-23 2011-07-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 1,2-Cyclic quinoline derivatives

Also Published As

Publication number Publication date
US20030125326A1 (en) 2003-07-03
CA2397694A1 (en) 2001-09-07
WO2001064218A2 (en) 2001-09-07
EP1261342A2 (en) 2002-12-04
JP2003525245A (en) 2003-08-26
WO2001064218A3 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU2001246477A1 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001240658A1 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
AU2001254672A1 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
AU2001252147A1 (en) Farnesyl protein transferase inhibitor combinations
AU2001235496A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
AU2001244166A1 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
PL348294A1 (en) Farnesyl protein transferase inhibitors
AU2001246478A1 (en) Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001239275A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001247882A1 (en) Tricyclic protein kinase inhibitors
AU2001256166A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
AU4228301A (en) Valve
AU2001253197A1 (en) Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
AU2001250321A1 (en) Homogentisate phytyl transferase
AU4020897A (en) 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
AU2001244167A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
AU2001272651A1 (en) Valves
AU2001242434A1 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2435199A (en) Farnesyl transferase inhibitors
HUP0202152A2 (en) Tricyclyc farnesyl protein transferase inhibitors
DK1339695T3 (en) Farnesyl transferase inhibitors
PL355887A1 (en) Farnesyl transferase inhibitors
AU3514302A (en) 0ovel farnesyl protein transferase inhibitors
AU2001282520A1 (en) Grk inhibitor
AU2001244863A1 (en) Apoptin-associating protein